Prerenal failure is used to designate a reversible form of acute renal dysfunction. However, the terminology encompasses several different conditions that vary considerably. The lack of a widely accepted definition for prerenal failure makes it impossible to determine the epidemiology, natural history, and association with adverse outcomes.
Introduction
Prerenal failure is widely accepted as a reversible form of renal dysfunction, caused by factors that compromise renal perfusion. The term has been used as part of a dynamic process that begins with a reversible condition, prerenal state, and can progress to an established disease, acute tubular necrosis (ATN). The terminology encompasses different conditions that vary considerably in the pathophysiology and course, including intravascular volume depletion, relative hypotension, compromised cardiac output, or hepatorenal syndrome (HRS). Diagnostic strategies have usually been based on demonstrating a fluid-responsive change in renal function; however, the type, volume of fluid required, and time for reversibility are not clearly designated. Recent attempts to define and stage acute kidney injury (AKI) have not specifically addressed this condition even though it is an integral part of the spectrum of AKI. In this review we discuss the pathophysiology of prerenal states and provide a framework for refining the diagnosis and management of prerenal failure.
The concept of kidney reserve: pre-prerenal state Experimental models have largely informed our current understanding of the physiology of the kidney in various settings associated with prerenal failure. Before the onset of clinically evident prerenal failure, the kidney passes through a phase of remarkable compensation called preprerenal failure [1] . Three main steps are involved in this compensatory mechanism: the cardiac output fraction that reaches the kidney, plasma flow filtration by the glomerulus (filtration fraction), and proportion of the glomerular filtrate that is reabsorbed by the tubules (Fig. 1) . Renal blood flow (RBF) depends on the tone of renal vascular resistance (RVR) in relation to systemic vascular resistance (SVR): if the RVR increases in relation to the SVR, the RBF decreases. At reduced levels of cardiac output, intrarenal factors are triggered, increasing renal arterial vascular tone and, consequently, decreasing the RBF. In order to maintain the intraglomerular pressure, efferent arteriolar resistance increases, preserving the filtration pressure even when the pressure in the afferent arteriole decreases to levels low enough to cease filtration. Augmented activity of the sympathetic nervous and renin-angiotensin-aldosterone systems, and vasopressin secretion increases the amount of filtered fluid that is reabsorbed by the renal capillaries and veins. These three mechanisms: control of blood flow to the kidney, fraction of plasma filtered, and amount of fluid reabsorbed by the kidney are the components responsible for the kidney reserve. However, the efficiency of these mechanisms has limits imposed by structural changes and the severity of the injury. The reserve is diminished by the presence of underlying arterial and intrinsic renal diseases that interfere with the control of renal blood flow, filtration fraction and reabsorbed function, as well as by drugs that interfere with the vascular or neural humoral control of these mechanisms. When these compensatory mechanisms are overwhelmed, a prerenal state is discernible.
Pathophysiology of prerenal failure
Several mechanisms are recognized as contributory to the development of a prerenal state. Maintenance of intraglomerular filtration pressure is the key component and is influenced by the presence of underlying disease that interferes with the control of renal blood flow, filtration fraction, and reabsorbed function. The afferent arteriole can dilate and maintain adequate perfusion pressure until the systemic blood pressure falls below approximately 80 mmHg. After this point the perfusion pressure starts to decline abruptly. Structural changes in the afferent arteriole interfere with the ability to decrease the vascular tone in response to changes in the wall pressure. Old age, arteriosclerosis, diabetic vasculopathy, chronic hypertension, and chronic kidney disease (CKD) are common causes impairing the appropriate vasodilatory response. This ability is also altered by drugs that interfere with prostaglandin release or the angiotensin action in the efferent arteriole, decreasing the potential arteriolar response to a fall in the glomerular pressure and predisposing patients to prerenal failure even during minor degrees of hypotension (Table 1) .
During mild to moderate reductions in cardiac output or intravascular volume, the action of angiotensin II in the efferent arteriole is responsible for the ability to preserve the filtration fraction. If this mechanism is already in use, further increases in angiotensin II in the kidney result in a more pronounced afferent arteriolar constriction, causing a fall in the perfusion pressure and the glomerular filtration rate.
Under normal circumstances, almost 80% of NaCl is reabsorbed by the end of the thick ascending limb of Henle's loop. If there is a failure in tubular reabsorbing mechanism, more NaCl will reach this point. The cells in the macula densa are sensitive to the increased delivery of NaCl and activate type 2 adenosine receptors resulting in vasoconstriction of the glomerular arterioles and retraction of glomerular tuft. As a consequence urine output is decreased and urinary excretion of sodium is reduced, providing a diagnostic flag of the tubular ischemic process. This tubuloglomerular feedback mechanism is subject to perturbations, particularly when loop diuretics are used. Loop diuretics reduce effective intravascular volume and impair the autoregulatory mechanism by interfering with the reabsorption of NaCl by the macula densa cells.
Spectrum of prerenal states
Although prerenal failure is common in different clinical settings and generally associated with renal hypoperfusion, its pathophysiology and consequences are quite diverse. Severe dehydration in the setting of profound diarrhea or vomiting results in hypotension and stimulates aldosterone and vasopressin through different mechanisms with the goal to retain salt and water to replenish the depleted environment. In other clinical scenarios, renal hypoperfusion can be present even in the presence of normal blood pressure [2] . Normotensive patients are predisposed to renal hypoperfusion when intrinsic renal structural changes from premorbid conditions interfere with the reserve mechanisms or extrinsic factors impair the compensatory mechanisms ( Table 1 ).
In hepatorenal syndrome type 1, considered a prerenal disease, the reduction in splanchnic and total vascular resistance occurs as a consequence of increased nitric oxide and endothelium-derived relaxing factor. With hepatic disease progression, there is a progressive rise in cardiac output and fall in SVR. The associated hypo-tension induces activation of the renin-angiotensin and sympathetic nervous systems causing increments in RVR, reducing GFR and sodium excretion. Any additional insult caused by gastrointestinal losses, bleeding, or therapy with a diuretic or a nonsteroidal anti-inflammatory drug precipitates further decline in GFR.
In acute heart failure, impaired cardiac output causes decreased glomerular perfusion pressure and increased venous pressure, reducing the glomerular filtration. Although extracellular fluid volume is increased, the effective (intravascular) blood volume is diminished. As a result, the renin-angiotensin-aldosterone system is activated, and the increased production of angiotensin II stimulates expression of endothelin 1 in the kidney, a potent proinflammatory vasoconstrictor. Additionally, patients with congestive heart failure frequently receive medications that further decrease the effective volume, such as diuretics, or affect the renal response to diminished perfusion, for example, angiotensin blockers.
Considering the physiologic process, especially in sepsis, the pattern of the urinary and biochemistry values may change during the progress of the disease. In sepsis, arterial vasodilatation is followed by activation of reninangiotensin, sympathetic nervous system, and arginine vasopressin release. The resultant renal vasoconstriction is associated with an increase in tubular sodium reabsorption and a decrease in urinary sodium concentration. As the disease process progresses and tubular dysfunction occurs, there is a conversion of decreased FE Na to increased FE Na [3] . A systematic review of septic AKI found that the urinary parameters were not useful in differentiating prerenal failure from ATN [4, 5] . Unfortunately, the time frame for the collection of these urinary and biochemical parameters and the relationship of other factors, for example, use of diuretics and aminoglycosides, to the onset of AKI need to be better determined.
In the pediatric population, intravascular fluid depletion is a common cause of AKI, particularly in the pediatric ICU admission. These patients often respond solely to fluid repletion, with a return of serum creatinine to baseline values within 24-48 h after fluid resuscitation. A study validating the pediatric RIFLE criteria in the ICU setting compared the renal outcome and mortality of patients with an early reversal AKI, patients presenting improvement in pRIFLE within 48 h of ICU admission, vs. patients with persistent AKI showing no improvement in pRIFLE by 48 h. Renal function improved within 48 h in 46% of patients with AKI at PICU admission. This early reversal AKI occurs more often in patients with pRIFLE R on admission than in those with pRIFLE I on admission. Fewer patients received RRT in the early reversal group than in the group with persistent AKI.
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Diagnosis of prerenal failure
The Acute Kidney Injury Network group has recently standardized the AKI definition and classification system; however, whether AKI refers only to ATN and other parenchymal diseases or includes prerenal failure remains to be determined. An elevation of serum creatinine or a reduction of urine output, which is easily reversible with improved hydration or improved renal perfusion pressure, is the current accepted definition of prerenal failure. Unfortunately these parameters are influenced by several factors. Serum creatinine levels are influenced by age, race, muscle mass, diet, volume of distribution, and drugs that alter the creatinine tubular secretion. Similarly, urine flow can vary according to the underlying GFR, tubular function, use of diuretics, and presence of osmotic forces.
Moran et al. previously demonstrated the effect of fluid accumulation on serum creatinine concentrations and showed that increasing total body water alters the volume of distribution of sCr, resulting in underestimation of its values [6, 7] . A diagnosis of prerenal failure thus requires a consideration of these factors and other conditions such as preexisting disease, time frame, and response to interventions.
The most important parameter to distinguish prerenal failure secondary to volume depletion or hypotension from ATN is the response to fluid expansion. The return of renal function to the previous baseline within 24-72 h is considered to represent prerenal disease, whereas persistent renal failure is called ATN. Unfortunately, there is no agreement on the amount, nature, and duration of fluid resuscitation needed to establish a prerenal state ( Table 1) . Laboratory tests to distinguish prerenal failure from ATN include close examination of the urine, plasma (P) urea/creatinine ratio, urine (U) osmolality, U/P osmolality, U/P creatinine ratio, urinary Na level, and fractional excretion of Na (FE Na ) ( Table 2 ) [8-15,16 ,17] . The serum U/P creatinine ratio helps to identify whether the oliguria is a result of water reabsorption (U/Pcr > 20) or loss of tubular function (U/Pcr < 20). The reabsorption of sodium is increased in prerenal states, caused by not only the increase in proximal tubular reabsorption of water but also the increase in aldosterone level secondary to hypovolemia. Common limitations for the use of FE Na are associated with the frequent use of diuretic therapy in oliguric patients and in the treatment of heart and liver failure. Also, in hypovolemia associated with vomiting or enhanced loss from nasogastric tubes, the loss of acid drives a higher bicarbonaturia and maintains urinary sodium and FE Na at higher than expected levels for a hypovolemic condition [18] . Besides, other causes of ATN are also associated with decreased FE Na : myoglobinuria [19] , contrast nephropathy [20] , obstructive nephropathy [21] , and acute glomerulonephritis [22] , among others [23] .
The fractional excretion of urea (FE UN ) has also been used to differentiate prerenal failure from ATN, especially when diuretics were used. FE UN relates inversely to the proximal reabsorption of water, and urea reabsorption leads to a decrease in FE UN and an increase in the BUN/ creatinine ratio. Carvounis et al. [12] found that FE UN has a high sensitivity (85%), a high specificity (92%), and a high positive predictive value; in that study a FE UN less than 35% was associated with a 98% chance of prerenal failure. Still, there are also some limitations for the use of FE UN . In osmotic diuresis and with the use of mannitol or acetazolamide, the proximal tubular reabsorption of salt and water is impaired, so there can be an increase in FE UN even in states of hypoperfusion [24] . The same can occur when a patient is given a high-protein diet or presents an excessive catabolism.
Urinary osmolality is also used to evaluate the urinary concentration ability, a function that becomes impaired in the early process of tubular dysfunction. A value greater than 500 mOsm/kg indicates that tubular function is still intact, although there are also some considerations about this index: a low-protein diet can impair the concentration ability of the urine and show a low osmolality even in prerenal states.
Unfortunately, these diagnostic parameters present frequent exceptions and the distinction between prerenal and renal causes is frequently not accurate. There are some promising new biomarkers for AKI that could provide us with the tools to distinguish between prerenal and established AKI [13, 16 ] . During the prerenal state, the persistent vasoconstriction associated with metabolic changes and inflammation promote the release of cell functional markers that can be detected in the blood and urine. However, at the current time there are no specific markers representing prerenal conditions. Urinary NGAL levels were evaluated in emergency room patients, although the AUC for NGAL (0.948) did not significantly differ from the curve for serum creatinine (0.921). There was very little overlap in NGAL values in patients with AKI and prerenal failure, whereas serum creatinine values overlapped significantly [16 ] .
In summary, current diagnosis of prerenal conditions is relatively insensitive and would benefit from additional research to define and classify the condition. Because of the broad differences in patients' reserve capacity and functional status, prerenal states may be triggered at different time points. Additionally, given the variety of insults and compensatory mechanisms triggered, it is unlikely that biomarkers of renal injury would be able to distinguish all these events.
Gaps in knowledge and future directions
As a consequence of the lack of standardized definition and observational studies that could differentiate prerenal failure from established AKI, the prognosis of prerenal failure has yet to be determined. There are no studies on the incidence and consequences of prerenal failure in various clinical settings, such as perioperative shock states including sepsis, burns, or cardiorenal syndrome. The long-term consequences of episodes of prerenal failure also need to be evaluated. In patients presenting with comorbid conditions and intrinsic factors associated with decreasing compensatory mechanisms, the frequency of subclinical episodes of prerenal failure is unknown. Whether the frequency and duration of these episodes can have an impact on the progression of renal dysfunction also has to be determined. The identification of high-risk states and high-risk process, as well as a standardized definition, could help future studies to investigate these questions.
The difference in pathophysiology and manifestation of prerenal state in these conditions suggests that our current approach to defining prerenal failure needs to be modified. The prerenal state could be classified depending on the underline capacity for compensation, the nature and the timing of the insult, and the adaptation to chronic comorbidities. The underlying reserve capacity can be normal, compromised, or absent. In patients with normal renal function and absence of comorbidities, all three mechanisms of compensation can occur: control of blood flow to the kidney, fraction of plasma filtered, and amount of fluid reabsorbed by the kidney. In these patients the recognition of the insult is fundamental to determine the initial therapy, as in early phases the therapy should be direct to the causative mechanism of the renal decompensation and can be rapid. For example, hypovolemic patients need fluid replacement and the reevaluation of renal function to receive the diagnostic of prerenal failure.
On the other hand, patients with already compromised kidney reserve are unable to use one or all of the compensatory mechanisms. Presence of CKD (stages I to III), CHF, and other comorbidities such as myeloma, compensated cirrhosis, or vascular alterations secondary to aging and use of ACE inhibitors is associated with decreased ability to compensate insults. In patients presenting low cardiac output, the appropriate therapy has to be tested: volume expansion or cardiac inotropy, and depending on the cause of decompensation, enough time has to be given to reevaluate the renal function. In patients with CHF or chronic compensated liver failure, activation of neural and hormonal system leads to a permanent utilization of adaptive mechanisms by the kidney. Prerenal state frequently occurs in CHF patients when contrast agents or higher doses of diuretic therapy are used, or in patients with chronic liver failure that present TGI bleeding, paracentesis, or higher dose of diuretic therapy.
In the complete absence of reserve, as in patients with CKD stages IV/V, CHF class IV, or decompensated cirrhosis, any additional insults can determine loss of function. Progressive deterioration in renal function evidenced by progressive fibrosis of the renal parenchyma can occur in patients in whom the adaptive mechanisms are maintained for long periods.
Conclusion
It is evident that research is urgently needed to bring further clarity in this field. We believe that the principles discussed above need to be considered when developing standardized definitions of prerenal states. Future studies would need to focus on populations at risk for prerenal failure and discover biomarkers representing the compensatory mechanisms triggered during prerenal states. It is reasonable to expect that several different markers may be used in combination to distinguish prerenal states from structural changes in the kidney. Recognizing reversible renal dysfunction early and accurately will enable timely intervention and likely enhance our ability to improve outcomes from AKI.
